Biomea Fusion (BMEA) Other Accumulated Expenses (2021 - 2026)
Biomea Fusion (BMEA) posted Other Accumulated Expenses of $159000.0 for Q1 2026, down 5.92% sequentially from $169000.0 in Q4 2025, and down 39.08% YoY from $261000.0 in Q1 2025.
Biomea Fusion (BMEA) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Biomea Fusion has reported Other Accumulated Expenses for 6 years, with the latest figure at $159000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 39.08% year-over-year to $159000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159000.0 (down 39.08% YoY) and the FY2025 annual result came in at $169000.0, down 16.75% from the prior year.
- Other Accumulated Expenses fell to $159000.0 in Q1 2026 per BMEA's latest filing, from $169000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $636000.0 in Q4 2022 and troughed at $144000.0 in Q3 2025.
- A 5-year average of $288235.3 and a median of $215000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 111.88% in 2022, then tumbled 69.81% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $636000.0 in 2022, then tumbled by 69.81% to $192000.0 in 2023, then grew by 5.73% to $203000.0 in 2024, then slipped by 16.75% to $169000.0 in 2025, then declined by 5.92% to $159000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $159000.0, $169000.0, and $144000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 191,000.00 |
| Mar 31, 2026 | 159,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Sep 30, 2025 | 144,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Mar 31, 2025 | 261,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Dec 31, 2023 | 192,000.00 |
| Sep 30, 2023 | 164,000.00 |
| Jun 30, 2023 | 399,000.00 |
| Mar 31, 2023 | 425,000.00 |
| Dec 31, 2022 | 636,000.00 |
| Sep 30, 2022 | 428,000.00 |
| Jun 30, 2022 | 449,000.00 |
| Mar 31, 2022 | 474,000.00 |
| Dec 31, 2021 | 480,000.00 |
| Sep 30, 2021 | 202,000.00 |